Hepatitis B In Silico Trials Capture Functional Cure, Indicate Mechanistic Pathways, and Suggest Prognostic Biomarker Signatures
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Javiera Cortés-Ríos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Computer Simulation, Hepatitis B, Chronic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
In silico trials, utilizing mathematical models calibrated with clinical data, present a transformative approach to expedite drug development. We propose a virtual trial framework for chronic Hepatitis B, accurately simulating clinical protocols, patient characteristics, and endpoints using a mechanistic mathematical model. Clinical trial simulations with this model successfully captured functional cure with standard‐of‐care therapies (nucleos(t)ide analogs and pegylated interferon) as well as complex clinical observations, facilitating mechanistic hypothesis generation and suggesting biomarker signatures that may predict treatment outcomes. In silico trials revealed that responders exhibited enhanced cytotoxic immunity and significant serum‐alanine transaminase increases, suggesting a potential response biomarker. However, a higher baseline Hepatitis B surface antigen did not proportionately increase cytotoxic antiviral immune responses, indicating a potential immune ceiling but in the face of increasing systemic antigen burden, therefore culminating in a lower treatment response. Virtual patients enabled the generation of large virology biomarker synthetic datasets, which empowered a machine learning model to predict functional cure in virtual patients with ~ 95% accuracy. This underscores the potential of in silico trials in enhancing clinical trials, generating mechanistic hypotheses, and accelerating chronic Hepatitis B drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, USA.
- Clinical Pharmacology Modelling & Simulation, GSK, Collegeville, Pennsylvania, USA.
- Clinical Pharmacology Modelling & Simulation, GSK, Waltham, MA, USA.
- Clinical Pharmacology Modelling & Simulation, GSK, Stevenage, UK.
ORCID-Profile: Javiera Cortés-Ríos, Tianjing Ren, Nathan Hanan, Anna Sher, William J Jusko, Rajat Desikan
Zitieren
APA
Cortés-Ríos, J., Ren, T., Hanan, N., Sher, A., Nader, A., Magee, M., Jusko, W. J., & Desikan, R. (2025). Hepatitis B In Silico Trials Capture Functional Cure, Indicate Mechanistic Pathways, and Suggest Prognostic Biomarker Signatures. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3718
Vancouver
Cortés-Ríos J, Ren T, Hanan N, Sher A, Nader A, Magee M, et al. Hepatitis B In Silico Trials Capture Functional Cure, Indicate Mechanistic Pathways, and Suggest Prognostic Biomarker Signatures. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3718
BibTeX
@article{CortsRos2025,
author = {Cortés-Ríos, Javiera and Ren, Tianjing and Hanan, Nathan and Sher, Anna and Nader, Ahmed and Magee, Mindy and Jusko, William J and Desikan, Rajat},
title = {Hepatitis B In Silico Trials Capture Functional Cure, Indicate Mechanistic Pathways, and Suggest Prognostic Biomarker Signatures},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3718}
}
EUVIMED